Scholars Central

OpinionPublished 7 Jan 2026

Biopharmaceutics Classification System: Drug Performance Prediction

Authors: Dr. Omar Al-Farsi

Department of Pharmaceutical Sciences, Crescent Health Institute, Al Noor University, Muscatra, Oman

Clinical Pharmacology & Biopharmaceutics

Volume 14 · Issue 4 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The Biopharmaceutics Classification System (BCS) is a key framework for predicting the in vivo performance of oral drugs by assessing solubility, permeability, and dissolution. It aids in formulation development, bioavailability studies, and regulatory decisions on bioequivalence. Advancements in solubility enhancement techniques are crucial for BCS Class II and IV drugs. Permeability and dissolution testing are continuously refined to improve predictive accuracy. The BCS also plays a role in regulatory science, influencing bioequivalence study waivers. Furthermore, it guides drug delivery system selection and emphasizes the importance of gastrointestinal physiology. The BCS framework is evolving with new technologies to enhance its utility in drug development.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Clinical Pharmacology & Biopharmaceutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Pharmacology & Biopharmaceutics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Dr. Omar Al-Farsi”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels